Previous studies identified recurrent fusion and duplication events in pediatric low-grade glioma (pLGG). In addition to their role in diagnosis, the presence of these events aid in dictating therapy and predicting patient survival. Clinically, BRAF alterations are most commonly identified using fluorescent in situ hybridization (FISH). However, this method is costly, labor-intensive and does not identify nonBRAF events. Here, we evaluated the NanoString nCounter gene expression system for detecting 32 of the most commonly reported fusion/duplication events in pLGG. The assay was validated on 90 pLGG samples using FISH as the gold standard and showed sensitivity and specificity of 97% and 98%, respectively. We next profiled formalin-fixed paraffin-embedded preserved biopsy specimens from 429 pLGG cases. 171 (40%) of the cases within our cohort tested positive for a fusion or duplication event contained within our panel. These events, in order of prevalence, were KIAA1549-BRAF 16;9 (89/171, 52.0%), KIAA1549-BRAF 15;9 (42/171, 24.6%), KIAA1549-BRAF 16;11 (14/171, 8.2%), FGFR1-TACC1 17;7 (13/171, 7.6%), MYBL1 duplication (5/171, 2.9%), KIAA1549-BRAF 18;10 (4/171, 2.3%), KIAA1549-BRAF 15;11 (2/171, 1.2%), FAM131B-BRAF 2;9 (1/171, 0.6%), and RNF130-BRAF 3;9 (1/ 171, 0.6%). This work introduces NanoString as a viable clinical replacement for the detection of fusion and duplication events in pLGG.
INTRODUCTION
Pediatric low-grade gliomas (pLGG) are the most common pediatric brain tumor and account for $35% of central nervous system tumors in children (1) (2) (3) (4) . pLGG includes a range of histologic types with WHO grade I pilocytic astrocytoma being the most frequent (3) . Clinically, pLGGs are generally slow growing lesions that can occur throughout the central nervous system and are surgically removed when possible. Complete surgical resection is the most significant predictor of improved survival in pLGG (5) . However, the extent of resection is often dependent on tumor location and hence, only feasible for a subset of cases. For example, tumors arising in the posterior fossa can be completely resected and thereby boast an excellent progression free survival (6) . However, for pLGGs located in the optic pathway, brainstem, or spinal cord, attempted resection can often lead to surgical-related morbidity (7) (8) . Historically, radiotherapy was used as the primary treatment for unresectable pLGG. However, the long-term effect of radiotherapy on pLGG patients is a major concern (9-11) and has recently been linked to delayed patient mortality (12) . This has resulted in a more conservative low-dose chemotherapy and debulking approach as the primary strategy for unresectable pLGG management, but this has shown variable levels of effectiveness (13) (14) (15) . Clinically, this is often attributed to the high degree of heterogeneity within this group which results in clinical courses ranging from prolonged growth arrest to continuous progression and potential recurrence (16, 17) . The high degree of heterogeneity and the resultant variability of clinical outcome generated an urgent need to identify biological and genetic markers capable of risk stratification.
The involvement of RAS-MAPK pathway dysregulation in pLGG was first suggested upon the identification of a novel duplication in chromosome 7q34 (18, 19) . Later, it was shown that this gain resulted in a gene fusion between BRAF and KIAA1549 (20) .
The breakpoints of the duplicated region fall within the BRAF and KIAA1549 genes, and result in a fusion between the 5 0 end of KIAA1549 and the 3 0 end of BRAF at the tandem duplication junction. This results in the N-terminal regulatory domain of BRAF being replaced, leading to constitutively enhanced kinase activity (21) . Five separate KIAA1549-BRAF fusion configurations were originally described including between exons 16;9, 15;9, 16;11, 18;10, and 19;9 in order of prevalence (19) . Fusions involving FAM131B and SRGAP3 with BRAF resulting in similar kinase activation have also been described, although at significantly lower frequencies (21, 22) . Subsequent findings showed that RAS-MAPK activation through BRAF fusions are present in both grade I and grade II malignancies, although significantly less frequent in the latter (21, (23) (24) (25) (26) (27) . The presence of BRAF fusion events in pLGG has been shown to aid in tumor diagnosis (28) , predict clinical outcome (29, 30) , and dictate the most appropriate therapeutic approach (31) (32) (33) , and, as such, represents a critical factor in the management of pLGG. Besides BRAF, additional fusions such as those involving FGFR1, MYB/MYBL1, QKI, and NTRK2/3 have also been described in pLGG (34) (35) (36) (37) . As is seen in the BRAF fusions, kinase activation is the resultant effect.
Due to their size and location, pLGG biopsies are generally processed as formalin-fixed paraffin-embedded (FFPE) tissue samples. As such, the use of these tissue samples for the purposes of BRAF fusion detection requires specially designed and validated assays that tolerate the degraded and fragmented material extracted from the FFPE specimens. Often fluorescent in situ hybridization (FISH) or real-time PCR based methodologies are used for clinical identification of BRAF fusion events in pLGG. FISH is sensitive for the detection of BRAF duplication but may have problems with specificity, particularly in aneuploid samples, and is labor-intensive and thus expensive to implement. Further, it does not give information regarding the fusion partner and will not detect nonBRAF fusions within the same test. Because of the number of possible partners, RT-PCR becomes impractical for identification of any but the most common fusion events. To develop and optimize a clinical grade test capable of robustly identifying a spectrum of pLGG fusion and duplication events in FFPE-preserved tissue samples, we have taken advantage of the NanoString nCounter gene expression system (38-40) on which we developed a pLGG-specific panel capable of detecting the majority of reported fusion and duplication transcripts described in pLGG. The sensitivity and specificity of this method were compared against standard FISH analysis and shown to be comparable. Lastly, we utilized the NanoString system to effectively characterize a cohort of clinical pLGG to illustrate the effectiveness of the method and to interrogate the prevalence of certain fusion events.
MATERIALS AND METHODS

Patient Samples
Upon institutional Research Ethics Board approval of the study, review of the pathology and oncology databases at the Toronto Hospital for Sick Children (SickKids) identified 634 patients diagnosed with pLGG from 1985 to 2016. Fiftyeight lacked sufficient material quantity for RNA extraction and therefore 576 were used in this study. Cases were comprised of FFPE samples and consisted of biopsied or subtotally resected masses where available. Before analysis, a hematoxylin and eosin-stained section from each sample was centrally reviewed for pathological diagnosis and grading according to WHO criteria (41) .
RNA Isolation
Total RNA was isolated from 5-to 10-mm scrolls of FFPE preserved tissue with the RNeasy FFPE extraction kit (QIAGEN, Valencia, CA) under the manufacturer's guidelines. RNA quantity and quality were assessed using the NanoDrop 2000 (Thermo Scientific, Waltham, MA). Quality was based on 260/280 values and samples between 1.9 and 2.1 were considered to be sufficient.
Fluorescent In Situ Hybridization
The FISH test was designed to detect the tandem duplication using BAC clones within the duplicated region at 7q34 (RP11-248P7 and RP11-837G3) and 7p12.1 control probes (RP11-478M17 and RP11-876P22). Probes were obtained from The Centre for Applied Genomics (The Hospital for Sick Children, Toronto, Ontario, Canada). The 7q34 clones were directly labeled with Spectrum Green fluorochrome and the control clones were directly labeled with Spectrum Orange fluorochrome. Paraffin FISH analysis was performed on 4-mm tumor sections. Slides were baked overnight to fix the section to the slide and pretreated using a Paraffin Pretreatment kit (Abbott, Chicago, IL). Sections were dehydrated prior to slide/probe codenaturation on the Thermobrite (Intermedico, Markham, Ontario, Canada). Denaturation conditions used for paraffin embedded slides/probes were 85 C for 7 minutes, followed by overnight incubation at 37 C. Slides were washed in 0.4Â SSC/0.3% NP40 at 73 C for 30 seconds, followed by 2Â SSC/0.1% NP40 at room temperature for 30 seconds. Slides were counterstained with DAPI. Nuclei were analyzed using a Axioplan2 epifluorescence microscope (Zeiss, Jena, Germany). Images were captured by an Axiocam MRm Camera (Imaging Associates, Bicester, UK) and analyzed using an imaging system with MetaSystems Isis Software version5.1.110 (MetaSystems, Boston, MA).
NanoString Fusion Detection
Five hundred nanograms of total RNA input was used on the NanoString nCounter system (nanoString Technologies, Seattle, WA) utilizing our newly generated pLGG panel (reagents are available from NanoString Technologies and codeset through the Hospital for Sick Children). Samples were processed on the nCounter Preparation Station and the cartridge scanned at 555 fields of view on the nCounter Digital Analyzer. Raw NanoString counts were background adjusted with a Poisson correction based on the negative control spikes included in each run. This was followed by a technical normalization using the 4 housekeeping transcripts included in each run (ABCF1, ALAS1, CLTC, and HPRT1). Data is viewed using a box plot and the extreme statistical outlier method was used to detect the presence of an expressed fusion. A fusion or duplication transcript is designated as expressed if the raw count was above the average of the internal positive control raw counts plus 3xIQR as per manufacturer suggestion.
RESULTS
Identification of NanoString Fusion and Duplication Transcript Targets
A comprehensive literature review of publications up until 2015 was completed to identify all fusion and duplication transcript events described in pLGG (20-23, 34, 36, 42-45) . Target inclusion was based on 2 requirements: the target must have been reported in a peer reviewed journal and the breakpoint sequence must be provided to allow for proper NanoString capture probe design. A schematic depicting the literature review process and filtering can be seen in Figure 1 . From this review, 1 duplication and 31 fusion events were selected for inclusion within the pLGG panel (Table 1 ). These included all 9 previously reported KIAA1549-BRAF fusion events across all known breakpoints including 13;9, 15;10, 15;11, 15;9, 16;10, 16;11, 16;9, 18;10, and 19;9. Further, BRAF's other fusion partners were included: MACF1, CLCN6, FAM131B, FXR1, GNAI1, MKRN1, and RNF130. Additionally, nonBRAF fusions were contained within the panel, including those involving FGFR1, MYB, MYBL1, RAF, SRGAP3, and QKI. Of note, the reported MYB and FGFR1 duplication events were not included in the final panel due to probe similarity between these and several other transcripts detected within the panel resulting in false positive detection (34) .
Protocol Overview and Result Interpretation
A sample run on the NanoString pLGG panel can be completed in 2 days. Sample RNA is mixed with the proprietary pLGG panel CodeSet targeting the events described in Table 1 as well as both positive and negative technical control probes as previously described (40) . CodeSet and sample are allowed to hybridize overnight for 20 hours. Excess CodeSet is then washed away and the hybridized CodeSet/ RNA complexes are next purified and immobilized onto the nCounter cartridge system to allow for data collection. The nCounter cartridge is then scanned to identify the unique fluorescent signatures (barcode) associated with each CodeSet probe. The barcodes are counted and a total of each target is tabulated. Raw NanoString counts are background adjusted and technically normalized based on the positive control spikes. Data is viewed using a box plot of the log values and the extreme statistical outlier method was used to detect the presence of an expressed fusion. A fusion or duplication transcript is designated as expressed if the raw count was above the average of the internal positive control raw counts plus 3xIQR.
An example of the panel output is shown in Figure 2 . In sample one, an instance of insufficient material quality is identified. This is a standard quality control step within the panel and is based on the detection of the 4 housekeeping transcripts included within the codeset. If the house-keeping control transcripts are not detected at sufficient levels (geometric mean for the 4 house-keeping genes >100 is the quality cut-off) and the issue is not deemed mechanical as per NanoString-specific internal quality control flags, the sample is concluded as having insufficient RNA quality. Our analysis identified that the age of the sample directly correlated with the likelihood of having insufficient RNA quality ( Supplementary Fig. S1 ). All samples falling below the required material quality are unsuitable for this method of fusion detection and as such, we advise that samples no older than 13 years be used on this platform. Samples 2-6 tested positive for 5 different fusion transcripts contained within the pLGG panel: KIAA1459-BRAF 16;11, FAM131B-BRAF 2;9, KIAA1459-BRAF 15;11, KIAA1459-BRAF 15;9, and KIAA1459-BRAF 16;9, respectively. As seen, each fusion call is easily made based on visualization of the results. 13 publications involved analyzing previously described fusion/duplication events. In such cases, we cite the manuscripts originally identifying the aberration.
Comparison to Fluorescent In Situ Hybridization
The current test used for the identification of BRAF 7q34 duplication events in most clinical labs is FISH. To compare the NanoString panel, we ran 90 fresh frozen or FFPEpreserved samples on the NanoString panel and compared the results to those observed via FISH (Supplementary Fig. S2) . Results from the comparison can be seen in Table 2 . Using FISH as the gold standard, we identified 2 discrepant cases using the NanoString panel, 1 false positive and 1 false negative. Both of these cases were further characterized using CytoScan HD (Affymetrix, Santa Clara, CA). In both cases, CytoScan confirmed the original FISH conclusion. It is important to further note that originally 95 samples were used for comparison, but 5 were excluded due to inconclusive FISH results. In these cases, NanoString was able to effectively identify a genotype.
In addition to comparable results to FISH, the pLGG panel provides a robust method of fusion and duplication detection in instances of inconclusive FISH results. Two examples of such are seen in Figure 3 . In Figure 3A , a sample wild type for the KIAA1549-BRAF fusion yielded inconclusive FISH results, requiring detailed follow-up due to the presence of 3 copies of chromosome 7 within the sample (later identified via Q-PCR). Comparably, when run on the pLGG panel, the sample was identified as wild type and required minimal analysis time for this conclusion. Likewise, in Figure 3B , the signal pattern identified via FISH suggested a tandem duplication of the region 7q34 of which 70% displayed a signal pattern suggestive of the presence of 3 chromosome copies, 2 with a duplicated 7q34 region, and 1 with a nonduplicated 7q34 region. A further 25% of nuclei appeared to have double chromosome 7 content as compared to the main clonal line with signals suggestive of 6 copies of chromosome 7, 3 of which harbored the fusion event. As seen, the pLGG panel identified the KIAA1549-BRAF 16;9 fusion event. 
Prevalence of Fusion Events in pLGG
The NanoString pLGG panel was used to identify the presence of fusion or duplication transcripts in pLGG samples treated at the Hospital for Sick Children from 1985 to 2015. We identified 634 cases diagnosed as low-grade gliomas including pilocytic astrocytoma (PA), low-grade astrocytoma NOS (LGA, NOS), ganglioglioma (GG), dysembryoplastic neuroepithelial tumor (DNET), diffuse astrocytoma (DA), pilomyxoid astrocytoma (PMA), pleomorphic xanthoastrocytoma (PXA), oligodendroglioma, central neurocytoma, and subependymal giant cell astrocytoma (SEGA). Of the 634, 576 had sufficient tissue quantity for RNA extraction and were run on the pLGG panel. 147 failed to meet the RNA quality cut-off due to the age of the sample as discussed above.
Of the 429 samples that yielded results from the pLGG panel, 166 (39%) and 5 (1%) samples tested positive for the presence of a fusion or duplication event, respectively (Fig. 4A) . These events, in order of prevalence, were KIAA1549-BRAF 16;9 (89/171, 52.0%), KIAA1549-BRAF 15;9 (42/171, 24.6%), KIAA1549-BRAF 16;11 (14/171, 8.2%), FGFR1-TACC1 17;7 (13/171, 7.6%), MYBL1 duplication (5/171, 2.9%), KIAA1549-BRAF 18;10 (4/171, 2.3%), KIAA1549-BRAF 15;11 (2/171, 1.2%), FAM131B-BRAF 2;9 (1/171, 0.6%), and RNF130-BRAF 3;9 (1/171, 0.6%) (Fig. 4B) . Based on histology, pilocytic astrocytoma contained the most fusion events, while oligodendroglioma, PXA, and DNETs housed no fusions tested for on this panel. A full breakdown of the histological classifications of fusion/duplication positive samples is seen in Figure 4C .
DISCUSSION
Constitutive activation of the oncogenic RAS-MAPK pathway is involved in many cancers including both adult (46) and pediatric glioma (21, (23) (24) (25) (26) (27) . Events leading to this activation are thought to be an early event in the development of these cancers, and are critical in aiding physicians in treating these tumors (18) (19) (20) (21) 47) . In this study, we developed a novel panel of fusion and duplication targets that are most commonly associated with pLGG to be run on the NanoString nCounter system. This system provided high quality results on a range of samples, including those preserved in FFPE. When compared to FISH, the NanoString platform had comparable performance parameters while decreased processing and turnaround times and providing detailed results on multiple fusion targets and breakpoints within a single test. We conclude that the use of the NanoString pLGG panel for fusion detection in pLGG is poised to replace current FISH methodologies. Over the last decade, several seminal papers identifying multiple sources of RAS-MAPK pathway activation via fusion events in pLGG have been identified (20-23, 34, 36, 42-45) . In light of this, we aimed to generate a test capable of identifying all reported fusion and duplication targets ( Fig. 1 and Table 1 ). NanoString, due to its proprietary reporter and capture probe designs is capable of up to 500 target detections per run (40) , and therefore is able to detect multiple fusion/duplication events per run. Target inclusion required that the reported fusion be published and have a concisely defined breakpoint. In instances of homology, the fusion targets more commonly reported were included. The final pLGG panel included 32 targets including 31 fusion and 1 duplication events. Importantly, the NanoString platform is amenable to expansion, meaning that newly identified fusions in pLGG can be added to the panel, assuming that no cross reactivity with the current CodeSet is observed.
An immediate benefit of the NanoString pLGG panel over current methods is relieving the need of intense interpretation of the results. As seen in Figure 2 , results are displayed in a boxplot format, with an extreme outlier indicative of a fusion event. This method is preferred as it does not depend on a normal distribution of data, allows for a single sample comparative analysis, and is highly stringent in its call cut-offs. However, due to this tight stringency, this method may be prone to false negative results and must have the stringency adjusted accordingly, although this was not observed within our analysis. Comparatively, FISH is often determined based on experimenter confidence, which may lead to unintentional erroneous or inconclusive results in cases with complex signal patterns. Two such cases are highlighted in Figure 3 , in which the NanoString panel robustly identified the aberration. These samples tested with FISH were difficult to interpret. In cases like these, secondary testing may be requested which is both costly and time-consuming.
Our comparison of FISH to NanoString showed comparable results in terms of sensitivity and specificity (Table 2) : 97% and 98% sensitivity and specificity were accomplished, respectively, using the NanoString panel, with 2 discrepant cases identified. With the false positive sample, NanoString identified a clear KIAA1549-BRAF 16;9 fusion, while FISH analysis appeared negative. Following up with CytoScan HD, a 658kb deletion between the KIAA1549 and BRAF genes was observed. This suggests that the fusion transcript is there, but generated by a rearrangement other than tandem duplication that was not detected using FISH. Although uncommon, a deletion-based mechanism of fusion formation has been previously reported (48) . In the false negative, NanoString identified a clear normal result, while FISH was positive for the duplication. RNA-SEQ follow-up identified a novel fusion event not previously described and hence, not included in our original panel and therefore not detected.
Importantly, other clinically approved methods such as RT-PCR as described by Tian et al. (42) , reliably report the presence of BRAF-KIAA1549 fusions in FFPE patient samples. However, as compared to NanoString, it is incapable of detecting multiple targets within 1 analysis. Therefore, the widespread breakpoints and fusion/duplication partners makes it a very time-consuming process. Alternatively, several laboratories utilize single-nucleotide polymorphism (SNP)-based assays to identify chromosomal abnormalities (49, 50) . This method has been shown to robustly identify fusion events in a wide array of pLGG samples with a straightforward analysis. However, SNP arrays are expensive, sometimes incompatible with FFPE preserved tissue, do not detect balanced rearrangements, and are often insensitive to single copy duplication events in samples frequently contaminated with normal tissue. The use of massively parallel sequencing based targeted panels such as the OncoPanel and OncoCopy have also been suggested for clinical use (51, 52) . These platforms are ideal due to their ability to identify polymorphisms, indels, small copy number changes and fusion events. Despite the appeal of these types of methods, it is important to consider the cost and time required, 2 factors critical to clinical use. The NanoString equipment is an FDA approved clinical grade machine on which this laboratory developed panel was developed. It takes 48 hours to complete and costs significantly less than other methods of fusion detection. Importantly, no library preparation or complex downstream analysis is required. Alternately, OncoPanel requires a library-preparation step, yielding turnaround times of 2 weeks (51). Further, the analysis of these platforms is extensive, furthering the required time for a conclusive mutation call (51) . Lastly, the cost of OncoPanel and OncoCopy are in excess of the $100/sample pricing (reagent costs) associated with the NanoString panel, although exact costs vary based on the test provider.
To show the utility of the platform, we profiled patient samples from the extensive cohort of pLGGs treated at the Hospital for Sick Children. This allowed us to test the prevalence of fusion events across a broad spectrum of low-grade gliomas. We identified a fusion or duplication event occurring in 40% of the 429 samples successfully tested (Fig. 4A ). This percentage is lower than previous reports, although most published work focuses on specific subtypes of pLGG, which yield higher frequencies of fusion events (21- 34-36, 52). The lower percentage reported here is potentially due to the inclusion of all histologic low-grade tumors within our cohort including those known to infrequently harbor fusion/duplication events (Fig. 4B) . In Figure 4C , we identify the specific genetic aberrations present in pLGG with respect to the fusion partners and their breakpoints. This revealed a high level of variability of the specific genetic targets matching previous reports, further substantiating the value of multiplex capabilities (19, 21, 22) . The identification of driving fusion events in pLGG is beneficial both diagnostically and therapeutically. It has previously been reported that fusion/duplication events are almost exclusively seen in low-grade tumors, aiding in diagnosing small specimens and highly heterogeneous samples (21-24, 27, 29, 34-36) . Further, certain fusion events and breakpoints have been shown to be enriched in particular histologic subtypes, especially in cases of rarer neuroepithelial tumors, and hence may aid in defining a tumor subclass (8) . Reports have also shown a location saturation of specific fusion events, and as such may aid in concisely defining a midline versus hemispheric lesion (28, 35) . While surgical resection remains the mainstay of treatment for patients with pLGG, in cases where complete resection is not possible, fusion status aids in providing the basis for targeted therapies. MEK inhibitors have been shown to block oncogenesis in mouse models harboring BRAF or RAF fusions (50) . Further, it has been shown that BRAF fusion positive patients are resistant to standard inhibitors of BRAFV600E (53). Currently, several clinical trials are taking place to investigate the potential exploitation of the fusion events such as the SIOP-E LOGGIC phase III trial.
The findings from this study support that the NanoString system is a robust platform for the identification of fusion and duplication events in pLGG. NanoString offers the ability to multiplex large numbers of genes, has reasonable input material requirements, is capable of complex gene analysis, and is functional with both frozen and FFPE preserved samples. We have successfully applied the NanoString panel to a large set of pLGGs treated at the Hospital for Sick Children. The resultant data identified that a large portion of these samples harbored fusion or duplication events involving a variety of gene partners and fusion breakpoints. To conclude, we believe that the NanoString pLGG panel is a logical alternative for clinical characterization of fusion and duplication events in pLGG. The observed prevalence and variety of fusion events in pLGG further support the need for modernized methods of detection, and NanoString should be highly considered for clinical implementation in the future.
